

**HOUSE . . . . . No. 2182**

**The Commonwealth of Massachusetts**

PRESENTED BY:

*Carmine Lawrence Gentile and Hannah Kane*

*To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General Court assembled:*

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

An Act to reduce incidence and death from pancreatic cancer.

PETITION OF:

NAME:	DISTRICT/ADDRESS:	DATE ADDED:
<i>Carmine Lawrence Gentile</i>	<i>13th Middlesex</i>	<i>1/12/2023</i>
<i>Hannah Kane</i>	<i>11th Worcester</i>	<i>1/12/2023</i>
<i>Lindsay N. Sabadosa</i>	<i>1st Hampshire</i>	<i>1/15/2023</i>
<i>Marcus S. Vaughn</i>	<i>9th Norfolk</i>	<i>1/16/2023</i>
<i>Angelo J. Puppolo, Jr.</i>	<i>12th Hampden</i>	<i>1/17/2023</i>
<i>Kimberly N. Ferguson</i>	<i>1st Worcester</i>	<i>1/17/2023</i>
<i>Susan Williams Gifford</i>	<i>2nd Plymouth</i>	<i>1/18/2023</i>
<i>Natalie M. Blais</i>	<i>1st Franklin</i>	<i>1/18/2023</i>
<i>Patricia A. Haddad</i>	<i>5th Bristol</i>	<i>1/18/2023</i>
<i>Kathleen R. LaNatra</i>	<i>12th Plymouth</i>	<i>1/18/2023</i>
<i>Joseph D. McKenna</i>	<i>18th Worcester</i>	<i>1/18/2023</i>
<i>F. Jay Barrows</i>	<i>1st Bristol</i>	<i>1/18/2023</i>
<i>Bradley H. Jones, Jr.</i>	<i>20th Middlesex</i>	<i>1/18/2023</i>
<i>Steven Owens</i>	<i>29th Middlesex</i>	<i>1/18/2023</i>
<i>Ryan C. Fattman</i>	<i>Worcester and Hampden</i>	<i>1/18/2023</i>
<i>David K. Muradian, Jr.</i>	<i>9th Worcester</i>	<i>1/19/2023</i>
<i>Vanna Howard</i>	<i>17th Middlesex</i>	<i>1/19/2023</i>
<i>Christopher Hendricks</i>	<i>11th Bristol</i>	<i>1/19/2023</i>

<i>Christopher M. Markey</i>	<i>9th Bristol</i>	<i>1/19/2023</i>
<i>Peter Capano</i>	<i>11th Essex</i>	<i>1/20/2023</i>
<i>Steven S. Howitt</i>	<i>4th Bristol</i>	<i>1/20/2023</i>
<i>Josh S. Cutler</i>	<i>6th Plymouth</i>	<i>1/20/2023</i>
<i>Sean Garballey</i>	<i>23rd Middlesex</i>	<i>1/24/2023</i>
<i>Patricia A. Duffy</i>	<i>5th Hampden</i>	<i>1/24/2023</i>
<i>Brian W. Murray</i>	<i>10th Worcester</i>	<i>1/25/2023</i>
<i>David F. DeCoste</i>	<i>5th Plymouth</i>	<i>1/25/2023</i>
<i>Kate Hogan</i>	<i>3rd Middlesex</i>	<i>1/25/2023</i>
<i>Kelly W. Pease</i>	<i>4th Hampden</i>	<i>1/26/2023</i>
<i>Kate Donaghue</i>	<i>19th Worcester</i>	<i>1/27/2023</i>
<i>Jack Patrick Lewis</i>	<i>7th Middlesex</i>	<i>1/30/2023</i>
<i>Rodney M. Elliott</i>	<i>16th Middlesex</i>	<i>1/30/2023</i>
<i>Brian M. Ashe</i>	<i>2nd Hampden</i>	<i>1/30/2023</i>
<i>Paul K. Frost</i>	<i>7th Worcester</i>	<i>1/31/2023</i>
<i>Michael P. Kushmerek</i>	<i>3rd Worcester</i>	<i>2/1/2023</i>
<i>Antonio F. D. Cabral</i>	<i>13th Bristol</i>	<i>2/2/2023</i>
<i>Thomas M. Stanley</i>	<i>9th Middlesex</i>	<i>2/2/2023</i>
<i>Carole A. Fiola</i>	<i>6th Bristol</i>	<i>2/3/2023</i>
<i>Paul A. Schmid, III</i>	<i>8th Bristol</i>	<i>2/3/2023</i>
<i>Kevin G. Honan</i>	<i>17th Suffolk</i>	<i>2/3/2023</i>
<i>Adrian C. Madaro</i>	<i>1st Suffolk</i>	<i>2/3/2023</i>
<i>William M. Straus</i>	<i>10th Bristol</i>	<i>2/6/2023</i>
<i>Carol A. Doherty</i>	<i>3rd Bristol</i>	<i>2/6/2023</i>
<i>David Paul Linsky</i>	<i>5th Middlesex</i>	<i>2/7/2023</i>
<i>Patrick Joseph Kearney</i>	<i>4th Plymouth</i>	<i>2/9/2023</i>
<i>Alyson M. Sullivan-Almeida</i>	<i>7th Plymouth</i>	<i>2/9/2023</i>
<i>David M. Rogers</i>	<i>24th Middlesex</i>	<i>2/10/2023</i>
<i>Jessica Ann Giannino</i>	<i>16th Suffolk</i>	<i>2/12/2023</i>
<i>Colleen M. Garry</i>	<i>36th Middlesex</i>	<i>2/13/2023</i>
<i>Mike Connolly</i>	<i>26th Middlesex</i>	<i>2/13/2023</i>
<i>Patrick M. O'Connor</i>	<i>First Plymouth and Norfolk</i>	<i>2/13/2023</i>
<i>Denise C. Garlick</i>	<i>13th Norfolk</i>	<i>2/15/2023</i>
<i>Donald R. Berthiaume, Jr.</i>	<i>5th Worcester</i>	<i>2/15/2023</i>
<i>Paul McMurtry</i>	<i>11th Norfolk</i>	<i>2/15/2023</i>
<i>James B. Eldridge</i>	<i>Middlesex and Worcester</i>	<i>2/18/2023</i>
<i>Christopher Richard Flanagan</i>	<i>1st Barnstable</i>	<i>2/23/2023</i>
<i>Natalie M. Higgins</i>	<i>4th Worcester</i>	<i>2/23/2023</i>
<i>John Barrett, III</i>	<i>1st Berkshire</i>	<i>2/23/2023</i>

<i>Steven George Xiarhos</i>	<i>5th Barnstable</i>	<i>2/24/2023</i>
<i>Angelo L. D'Emilia</i>	<i>8th Plymouth</i>	<i>2/24/2023</i>
<i>Paul R. Feeney</i>	<i>Bristol and Norfolk</i>	<i>3/5/2023</i>
<i>Jacob R. Oliveira</i>	<i>Hampden, Hampshire and Worcester</i>	<i>3/10/2023</i>
<i>Kate Lipper-Garabedian</i>	<i>32nd Middlesex</i>	<i>3/12/2023</i>
<i>Tommy Vitolo</i>	<i>15th Norfolk</i>	<i>3/15/2023</i>
<i>Mathew J. Muratore</i>	<i>1st Plymouth</i>	<i>3/17/2023</i>
<i>Mindy Domb</i>	<i>3rd Hampshire</i>	<i>3/24/2023</i>
<i>Marc T. Lombardo</i>	<i>22nd Middlesex</i>	<i>3/29/2023</i>
<i>Todd M. Smola</i>	<i>1st Hampden</i>	<i>4/10/2023</i>
<i>Tram T. Nguyen</i>	<i>18th Essex</i>	<i>4/12/2023</i>
<i>Joan B. Lovely</i>	<i>Second Essex</i>	<i>4/12/2023</i>
<i>Norman J. Orrall</i>	<i>12th Bristol</i>	<i>4/24/2023</i>
<i>Michael J. Soter</i>	<i>8th Worcester</i>	<i>4/24/2023</i>
<i>Sally P. Kerans</i>	<i>13th Essex</i>	<i>5/3/2023</i>
<i>Adrienne Pusateri Ramos</i>	<i>14th Essex</i>	<i>6/15/2023</i>
<i>Kay Khan</i>	<i>11th Middlesex</i>	<i>7/17/2023</i>
<i>Bruce E. Tarr</i>	<i>First Essex and Middlesex</i>	<i>7/20/2023</i>
<i>Samantha Montaño</i>	<i>15th Suffolk</i>	<i>7/20/2023</i>
<i>David T. Vieira</i>	<i>3rd Barnstable</i>	<i>7/21/2023</i>
<i>Jonathan D. Zlotnik</i>	<i>2nd Worcester</i>	<i>7/28/2023</i>
<i>Alan Silvia</i>	<i>7th Bristol</i>	<i>8/4/2023</i>
<i>Paul J. Donato</i>	<i>35th Middlesex</i>	<i>8/7/2023</i>
<i>Michelle L. Ciccolo</i>	<i>15th Middlesex</i>	<i>8/7/2023</i>

**HOUSE . . . . . No. 2182**

---

---

By Representatives Gentile of Sudbury and Kane of Shrewsbury, a petition (accompanied by bill, House, No. 2182) of Carmine Lawrence Gentile, Hannah Kane and others for legislation to reduce incidence and death from pancreatic cancer. Public Health.

---

---

[SIMILAR MATTER FILED IN PREVIOUS SESSION  
SEE HOUSE, NO. 2304 OF 2021-2022.]

**The Commonwealth of Massachusetts**

\_\_\_\_\_  
**In the One Hundred and Ninety-Third General Court  
(2023-2024)**  
\_\_\_\_\_

An Act to reduce incidence and death from pancreatic cancer.

*Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:*

1 SECTION 1. Chapter 111 of the General Laws is hereby amended by adding the  
2 following section:-

3 Section 238. (a) The department shall administer a comprehensive pancreatic cancer  
4 initiative to provide coordinated pancreatic cancer prevention, screening, education and support  
5 programs in the commonwealth. The department may develop and implement other initiatives  
6 regarding pancreatic cancer awareness, research and care that the department determines will  
7 further the purposes of this section.

8 (b) There shall be a pancreatic cancer advisory council within the department. The  
9 council shall be appointed and convened by the commissioner and shall consist of 13 members

10 representing interdisciplinary fields including, but not limited to, oncology, palliative care,  
11 medicine, nursing, social work, pharmacy, spirituality and the area of patient and family  
12 caregiver advocacy, including health professionals having expertise treating pancreatic cancer  
13 patients and their families; provided, at least 1 member shall be a representative of the Pancreatic  
14 Cancer Action Network and 1 member shall be a representative of the American Cancer Society  
15 Cancer Action Network. The commissioner may appoint other members that the commissioner  
16 deems appropriate. Council members shall serve for a period of 3 years at the pleasure of the  
17 commissioner. The members shall elect a chair and vice chair whose duties shall be established  
18 by the council. The department shall provide a place for regular meetings of the council, which  
19 shall meet at least monthly.

20 Council members shall receive no compensation for their services but shall be allowed  
21 actual and necessary expenses in the performance of their council duties.

22 The council shall:

23 (1) Investigate and make recommendations for a system to certify and approve hospital  
24 systems that meet National Pancreatic Cancer Foundation criteria and post this information on an  
25 appropriate state website and on advocacy organization websites.

26 (2) Identify institutions and hospital systems which could meet the criteria in areas that  
27 are geographically underserved and provide them with incentives to develop the necessary  
28 resources to comply in order to assure that all residents have access to hospitals that meet the  
29 criteria.

30 (3) Investigate and make recommendations for the establishment of a multi-provider  
31 consortium to develop and disseminate amongst each other best practice algorithms, decision

32 aids for electronic health record systems, and quality metrics for all phases of care in pancreatic  
33 cancer. The consortium shall partner with other entities including, but not limited to, patient  
34 organizations, National Institute of Health and the American Cancer Society Cancer Action  
35 Network to develop and maintain a portfolio of statewide clinical trials in pancreatic cancer.

36 (4) Disseminate targeted communications to primary care providers and their office staff  
37 to connect them with the consortium members and resources which are local to their practices.

38 (5) Utilize the local resources of the consortium members to fully operationalize existing  
39 state initiatives to identify existing cancer support services, survivorship care and counseling and  
40 to expand these initiatives to meet current needs.

41 (6) Develop and support the use in all hospitals of a standard consent form for pancreatic  
42 cancer patients to consent to donate their tissue samples without restrictions for tissue collection  
43 and banking for research.

44 (b) The department, in conjunction with the pancreatic cancer advisory council, shall  
45 conduct a comprehensive study to ascertain the prevalence and incidence of pancreatic cancer in  
46 the commonwealth, the unmet needs of persons with pancreatic cancer and their families, time-  
47 of-diagnosis statistics and likely risks for pancreatic cancer. Information collected by the study  
48 shall include, but not be limited to, the following:

49 (1) germline testing results;

50 (2) molecular tumor analysis in patients with metastatic disease;

51 (3) hospitals treating the highest volume of pancreatic cancer patients;

52 (4) information on stage of diagnosis;

53 (5) treatment rendered, including chemotherapy, radiation therapy, surgical treatment,  
54 neoadjuvant and adjuvant therapy;

55 (6) patient outcomes;

56 (7) number of patients diagnosed who did not receive any treatment or palliative care;  
57 and

58 (8) number of pancreatic resections performed at each hospital and associated outcomes.

59 (c) The department, in conjunction with the pancreatic cancer advisory council, shall  
60 develop and implement a statewide public education and community outreach program to inform  
61 the general public about genetic risks, signs, symptoms, and pre-malignant conditions associated  
62 with pancreatic cancer, including new-onset diabetes, and the availability of clinical trials for  
63 those with pancreatic cancer. In developing and implementing the program, the commissioner  
64 shall consult with similar programs including, but not limited to, anti-tobacco, obesity and other  
65 pre-malignant conditions associated with pancreatic cancer. The department shall add pancreatic  
66 cancer to the list of diseases that its programs target with counseling for tobacco discontinuation,  
67 diet and weight management.

68 SECTION 2. The commissioner of insurance shall survey health insurers in the  
69 commonwealth to ascertain coverage benefits of genetic testing for pancreatic cancer across  
70 health insurance plans, and present its findings to the committee on health care financing and the  
71 committee on financial services no later than June 30, 2022.

72 SECTION 3. The center for health information and analysis shall conduct a review and  
73 update of its mandated benefit review of pancreatic cancer screenings as reported in the center's

74 report titled “Mandated Benefit Review of S.B. 471: An Act relative to pancreatic cancer  
75 screening,” dated July 2014, including an update of the cost analysis for pancreatic cancer  
76 screening for high-risk individuals. The center shall present its findings and update to the  
77 committee on health care financing and the committee on financial services no later than June  
78 30, 2022.

79 SECTION 4. The initial meeting of the pancreatic cancer advisory council shall convene  
80 no later than 60 days after the effective day of this act.